On October 2, 2017 the Nobel Prize for Medicine was awarded to a trio of American scientists for their insights into the molecular mechanisms controlling circadian rhythms. Jeffrey C Hall, Michael Rosbash and Michael W Young have spent their careers fathoming out how plants and animals are able to adapt their biological rhythm to the Earth's rotation. This interplay is essential in regulating a vast array of biological functions including sleeping and feeding patterns, core body temperature, hormone production, brain wave activity, and blood pressure. When this synchronization goes awry, an individual's wellbeing can be compromised. The impact of this fundamental process on medicine is becoming increasingly apparent, as attested by the Nobel award. However, translating mechanistic insight into understanding and developing practical ways to treat disease is a major challenge.

Many of us have experienced a mismatch between our body's circadian rhythm and the local environment. Jet lag, for example, is a common chronobiological disorder that describes a range of symptoms experienced while adapting to a different light-dark schedule following a flight to a new time zone. Usually, circadian rhythms can be adjusted to the local environment by external cues, such as light, which is why jet lag is usually temporary. The body achieves this by secreting melatonin, a hormone that regulates sleep and wakefulness. Its levels peak at night and fall away following daybreak, allowing the circadian clock to synchronize with sleep-wake timing. An inability to do this for prolonged periods of time - due to lifestyle choice or genetic disruption of circadian clock regulation - can cause health problems.

?twb.32w?\>The Institute of Medicine estimates that in the USA alone, 50-70 million adults have a chronic sleep disorder that contributes to poor health, while the UK Sleep Council estimate that more than a third of Britons sleep for less than 6 hours a night. This imposes a profound burden to a population's productivity, safety and quality of life. Sufficient sleep (usually defined as 7-9 hours per night for an adult) is necessary to ensure optimal functioning of many key biological processes, and numerous studies have associated chronic sleep disorders with increased risk of heart disease, high blood pressure, obesity, diabetes, neurological disorders and all-cause mortality. Yet association does not imply causation, and determining whether sleep deprivation directly contributes to a disorder is a more complicated undertaking.

In an attempt to address this challenge, a recent study published on September 6, 2017 in *The Lancet Psychiatry* provided strong evidence that insomnia is a causal factor in the occurrence of psychotic experiences and other mental health problems. A randomized controlled trial (OASIS; Oxford Access for Students Improving Sleep) was conducted in which 3,755 university students with insomnia received either internet-based cognitive behavioral therapy (CBT), or usual care consisting of little or no treatment. Individuals treated with CBT for 10 weeks exhibited reduced insomnia, paranoia and hallucinations compared to individuals in the usual practice group. Although CBT intervention needs to be tested in more diverse cohorts, these results provide strong evidence that sleep improvement has the potential to improve mental health, and should perhaps be given greater priority as a means to treat mental health disorders.

It is also becoming apparent that many aspects of sleep are heritable, and genes affecting numerous sleep traits have been identified. Thanks in part to the seminal work of Hall, Rosbash and Young, in conjunction with the primary circadian clock is a molecular circadian clock that provides tissues with an internal self-sustaining oscillator. This secondary clock is inherent to most cell types and functions to co-ordinate thousands of genes into unique phases via a local transcription/translation-based feedback loop. Mutations in components of this feedback loop can precipitate sleep disorders. For example, *Cell* recently published a study showing that a mutation in the human circadian clock gene, *CRY1*, is associated with a familial delayed sleep phase disorder (DSPD). This *CRY1* variant lengthens the circadian molecular rhythm, thus providing a mechanistic link to the clinical manifestation in which individuals exhibit "night owl" behavior.

What is becoming clear is that the quality of sleep, rather than just the quantity of sleep, is crucial in keeping disease at bay. David Holzman's group (Stanford University, USA) recently reported that a single disrupted night's sleep increases amyloid-beta (an Alzheimer's disease biomarker) in the cerebrospinal fluid (CSF) of healthy adults, compared to amyloid-beta levels following an uninterrupted night. Several bad nights' sleep was also associated with higher levels of tau in the CSF, a protein associated with neurodegenerative diseases. Crucially, this effect was specific for slow wave activity during non-REM sleep, not sleep duration or efficiency, highlighting the importance of a good night's sleep.

New technologies are empowering people to improve their sleep habits. Wearable activity monitors are available to assess sleep length, and bright light therapy can be used to reset the circadian rhythm. Even switching to night shift options on mobile phones can reduce the disruption of melatonin production, helping to promote better sleep practices. Nevertheless, the progress made in behavioral interventions needs to be matched with better pharmacological options. Given the diverse and overlapping roles of the body clock, a huge hurdle is finding molecular targets that will not result in profound side-effects when targeted by a biologic. Genome-wide studies have identified many genes that are associated with sleep disorders, but the clinical utility of these associations need to be determined. By complementing functional genomics studies with high-throughput screening of drug candidates using disease-relevant preclinical models, it is hoped that viable candidates will be identified.

Perhaps one day the timing of drug administration or a surgical procedure will be coordinated with an individual's body clock to improve patient care. Whether this vision of precision medicine materializes, only time will tell.
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